Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits resistance to therapies, including checkpoint inhibitors (CPI), due to its low immunogenicity and immunosuppressive tumor microenvironment.
• The PDAC stroma promotes hypoxia and recruits immunosuppressive cells, hindering effective anti-tumor immune responses.
• Only a small subset of PDAC tumors with microsatellite instability (<2%) respond to CPI monotherapy.

Purpose of the Study:

• To review current strategies for overcoming the immunosuppressive microenvironment in PDAC.
• To explore combination therapies involving CPI aimed at enhancing tumor immunogenicity and T-cell activation.
• To highlight the potential of translational studies in identifying predictive biomarkers for immunotherapy response.

Main Methods:

• Review of current research and clinical trials on PDAC immunotherapy.
• Analysis of strategies targeting the tumor stroma and hypoxic microenvironment.
• Investigation of adoptive T-cell transfer and biomarker discovery.

Main Results:

• Combination therapies are being developed to increase PDAC immunogenicity and effector T-cell recruitment.
• CPI combinations with vaccines, oncolytic viruses, MEK inhibitors, and hypoxia/stroma-targeting agents are under investigation.
• Translational studies are crucial for identifying biomarkers predicting clinical outcome and immunotherapy response.

Conclusions:

• Overcoming PDAC's immunosuppressive microenvironment is key to improving treatment efficacy.
• Combination immunotherapy strategies hold promise for enhancing anti-tumor immunity in PDAC.
• Biomarker identification through translational research is essential for personalized immunotherapy in PDAC.